Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 45Gastrointestinal 4Thoracic 3Gynecologic 3Genitourinary 3Head & Neck 2

Conditions

Urinary Bladder Neoplasms 8Prostatic Neoplasms 7Ovarian Neoplasms 6Breast Neoplasms 6Carcinoma, Transitional Cell 5Stomach Neoplasms 4Pancreatic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Neoplasms 3Neoplasm Metastasis 3Esophageal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Wilms Tumor 1Uterine Cervical Neoplasms 1Tumor Virus Infections 1Thrombocytosis 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrent Bladder Urothelial Carcinoma 1Recurrence 1

Interventions

pembrolizumab 33Nivolumab 15atezolizumab 9Cyclophosphamide 7Paclitaxel 6Ipilimumab 6spartalizumab 5fludarabine 5Docetaxel 5durvalumab 4avelumab 4Immune Checkpoint Inhibitors 4Carboplatin 4olaparib 3cemiplimab 3cabozantinib 3Specimen Handling 3Oxaliplatin 3Magnetic Resonance Spectroscopy 3Leucovorin 3Interleukin-2 3Gemcitabine 3Fluorouracil 3Cisplatin 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3sacituzumab govitecan 2obinutuzumab 2lenvatinib 2epacadostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Albumin-Bound Paclitaxel × Genitourinary × Clear all
NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03961698 2023-08-14

MARIO-3

Infinity Pharmaceuticals, Inc.

Phase 2 Unknown
91 enrolled
BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT04060342 2022-08-18

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Gossamer Bio Inc.

Phase 1 Terminated
61 enrolled
BreastGastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡